NO20001219L - Blanding for medikament-administrasjon - Google Patents

Blanding for medikament-administrasjon

Info

Publication number
NO20001219L
NO20001219L NO20001219A NO20001219A NO20001219L NO 20001219 L NO20001219 L NO 20001219L NO 20001219 A NO20001219 A NO 20001219A NO 20001219 A NO20001219 A NO 20001219A NO 20001219 L NO20001219 L NO 20001219L
Authority
NO
Norway
Prior art keywords
mixture
drug administration
drug
composition
approximation
Prior art date
Application number
NO20001219A
Other languages
English (en)
Other versions
NO20001219D0 (no
Inventor
Lisbeth Illum
Yu-Hui Cheng
Peter James Watts
Stanley Steward Davis
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of NO20001219D0 publication Critical patent/NO20001219D0/no
Publication of NO20001219L publication Critical patent/NO20001219L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytisk blanding omfattende polymeriske mikro- partikler, inkludert et medikament og en fettsyre, hvilken blanding kan tilpasses for å gi en fngivelses-hastighet som er tilnærmet lineær med tid, og uten å gi en betydelig sprengeffekt.
NO20001219A 1997-09-09 2000-03-09 Blanding for medikament-administrasjon NO20001219L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system
PCT/GB1998/002692 WO1999012549A2 (en) 1997-09-09 1998-09-07 Controlled release microsphere delivery system

Publications (2)

Publication Number Publication Date
NO20001219D0 NO20001219D0 (no) 2000-03-09
NO20001219L true NO20001219L (no) 2000-03-09

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001219A NO20001219L (no) 1997-09-09 2000-03-09 Blanding for medikament-administrasjon

Country Status (10)

Country Link
EP (1) EP1011680A2 (no)
JP (1) JP2001515862A (no)
AR (1) AR017079A1 (no)
AU (1) AU745511B2 (no)
CA (1) CA2302762A1 (no)
GB (1) GB9718986D0 (no)
NO (1) NO20001219L (no)
NZ (1) NZ502710A (no)
WO (1) WO1999012549A2 (no)
ZA (1) ZA987762B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
KR101139112B1 (ko) 2002-06-25 2012-04-30 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
WO2004039411A2 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
KR20070046892A (ko) 2004-08-31 2007-05-03 화이자 프로덕츠 인크. 저용해도 약물 및 중합체를 포함하는 제약 투여형
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
CA2665101A1 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
ES2791698T3 (es) 2006-12-18 2020-11-05 Takeda Pharmaceuticals Co Composición de liberación sostenida y método para producir la misma
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2695178C (en) 2007-07-31 2015-06-23 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
CN103458895B (zh) * 2010-11-25 2014-07-09 山东绿叶制药有限公司 罗替戈汀、其衍生物或罗替戈汀或其衍生物药用盐的组合物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
KR102045721B1 (ko) * 2019-03-27 2019-11-18 주식회사 씨트리 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine

Also Published As

Publication number Publication date
EP1011680A2 (en) 2000-06-28
NZ502710A (en) 2001-09-28
NO20001219D0 (no) 2000-03-09
AU745511B2 (en) 2002-03-21
AU8992598A (en) 1999-03-29
WO1999012549A3 (en) 1999-05-06
CA2302762A1 (en) 1999-03-18
AR017079A1 (es) 2001-08-22
GB9718986D0 (en) 1997-11-12
ZA987762B (en) 2000-02-28
WO1999012549A2 (en) 1999-03-18
JP2001515862A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
NO20001219L (no) Blanding for medikament-administrasjon
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
EE03137B1 (et) Veterinaarravim ja protsess selle valmistamiseks
AU2901489A (en) Onset-hastened/enhanced analgesia using s(+) ketoprofen
EP0130779A3 (en) Pharmaceutical composition suitable for intestinal administration
MY111879A (en) Pharmaceutical formulations.
DE69637961D1 (de) Verabreichung von biologisch aktiven polypeptiden
IS1858B (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
DK0954290T3 (da) Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose
NO942325D0 (no) Transdermalt administrert system som inneholder acetylsalicylsyre for tromboseterapi og cancerprofylakse
AU6346586A (en) Therapeutic agents
HK1018590A1 (en) Administration regimen of h+, k+-atpase inhibitors
DK0904067T3 (da) Transdermalt indgivet dextromethorpan som hostestillende middel
NO955126L (no) Mat-og/eller farmasöytisk blanding med lavt polyamininnhold og terapeutiske anvendelser derav
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
ATE137668T1 (de) Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung
AU6889196A (en) Long active composition for rectal administration
LV11728A (lv) Farmaceitiska kompozicija
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DK0770082T3 (da) Dioxo-thiopyrano-pyridin-carboxylsyrederivater og deres anvendelse som lægemidler
PL334093A1 (en) Application of comt inhibitors in production of drugs preventing occurence of vascular disorders in case of diabetes
ATE46442T1 (de) Arzneimittel zur behandlung chronisch entzuendlicher darmerkrankungen.
MX9701967A (es) Uso de aparato de inyeccion accionado neumaticamente sin aguja.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application